Organization
Denali Therapeutics
8 clinical trials
Clinical trial
A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label ExtensionStatus: Active (not recruiting), Estimated PCD: 2025-11-01
Clinical trial
A Study of the Pharmacokinetics of [14C]-DNL343 Following a Single Oral Dose in Healthy Male ParticipantsStatus: Recruiting, Estimated PCD: 2024-05-01
Clinical trial
A Phase 1/2, Multicenter, Open-Label Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL310 in Pediatric Participants With Hunter SyndromeStatus: Active (not recruiting), Estimated PCD: 2027-07-01
Clinical trial
A Phase 2/3, Multicenter, Double-Blind, Randomized Study to Determine the Efficacy and Safety of DNL310 vs Idursulfase in Pediatric Participants With Neuronopathic or Non-Neuronopathic Mucopolysaccharidosis Type IIStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)Status: Recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-06-08
Clinical trial
A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study, Followed by an Open-Label Extension, to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral SclerosisStatus: Active (not recruiting), Estimated PCD: 2022-12-15